Sign In

Study

Atopic Dermatitis Standing Cohort Using a Cohort of Kaiser Permanente Northern California Members

A cohort study of Kaiser Permanente Northern California patients with moderate-to-severe atopic dermatitis (AD) will be used to estimate baseline characteristics and background incidence rates of safety events. Data from this study will provide valuable information regarding the current incidence rates of adverse outcomes among patients with AD. Safety events of interest include: viral reactivation, malignancies, lymphoproliferative disorders, thrombocytopenia, major/minor bleeding events, major adverse cardiovascular events, alterations in lipid profiles, and thromboembolism.
Investigator: Hedderson, Monique
Funder: Pfizer Inc.